Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
51
CMPS Quote, Financials, Valuation and Earnings
Last price:
$5.63
Seasonality move
:
12.2%
Day range:
$5.06 - $5.68
52-week range:
$2.25 - $7.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
14.51x
Volume:
1.7M
Avg. volume:
1.9M
1-year change:
37.2%
Market cap:
$545.4M
Revenue:
--
EPS (TTM):
-$2.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CMPS
Compass Pathways Plc
|
-- | -$0.41 | -- | -37.8% | $17.00 |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $7.99 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CMPS
Compass Pathways Plc
|
$5.68 | $17.00 | $545.4M | -- | $0.00 | 0% | -- |
|
APM
Aptorum Group Ltd.
|
$1.40 | -- | $10M | 8.94x | $0.00 | 0% | 6.32x |
|
AUTL
Autolus Therapeutics Plc
|
$1.57 | $9.52 | $417.8M | -- | $0.00 | 0% | 8.15x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$5.09 | $17.94 | $3.2M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$4.43 | $104.00 | $18.4M | -- | $0.00 | 0% | -- |
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.69 | $7.99 | $200.8M | -- | $0.00 | 0% | 2,803.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CMPS
Compass Pathways Plc
|
48.35% | 2.199 | 6.4% | 0.94x |
|
APM
Aptorum Group Ltd.
|
-- | -9.132 | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | 0.602 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CMPS
Compass Pathways Plc
|
-$14.9K | -$40.3M | -129.92% | -159.15% | -- | -$34.8M |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
Compass Pathways Plc vs. Competitors
-
Which has Higher Returns CMPS or APM?
Aptorum Group Ltd. has a net margin of -- compared to Compass Pathways Plc's net margin of --. Compass Pathways Plc's return on equity of -159.15% beat Aptorum Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M APMAptorum Group Ltd.-- -- -- -
What do Analysts Say About CMPS or APM?
Compass Pathways Plc has a consensus price target of $17.00, signalling upside risk potential of 199.3%. On the other hand Aptorum Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 10614.29%. Given that Aptorum Group Ltd. has higher upside potential than Compass Pathways Plc, analysts believe Aptorum Group Ltd. is more attractive than Compass Pathways Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc6 1 0 APMAptorum Group Ltd.0 0 0 -
Is CMPS or APM More Risky?
Compass Pathways Plc has a beta of 1.933, which suggesting that the stock is 93.331% more volatile than S&P 500. In comparison Aptorum Group Ltd. has a beta of -0.206, suggesting its less volatile than the S&P 500 by 120.612%.
-
Which is a Better Dividend Stock CMPS or APM?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aptorum Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. Aptorum Group Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or APM?
Compass Pathways Plc quarterly revenues are --, which are larger than Aptorum Group Ltd. quarterly revenues of --. Compass Pathways Plc's net income of -$136.9M is higher than Aptorum Group Ltd.'s net income of --. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while Aptorum Group Ltd.'s PE ratio is 8.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus 6.32x for Aptorum Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M APMAptorum Group Ltd.6.32x 8.94x -- --
-
Which has Higher Returns CMPS or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Compass Pathways Plc's net margin of -373.3%. Compass Pathways Plc's return on equity of -159.15% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About CMPS or AUTL?
Compass Pathways Plc has a consensus price target of $17.00, signalling upside risk potential of 199.3%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 506.51%. Given that Autolus Therapeutics Plc has higher upside potential than Compass Pathways Plc, analysts believe Autolus Therapeutics Plc is more attractive than Compass Pathways Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc6 1 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is CMPS or AUTL More Risky?
Compass Pathways Plc has a beta of 1.933, which suggesting that the stock is 93.331% more volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock CMPS or AUTL?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or AUTL?
Compass Pathways Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Compass Pathways Plc's net income of -$136.9M is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus 8.15x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M AUTLAutolus Therapeutics Plc8.15x -- $21.1M -$78.6M
-
Which has Higher Returns CMPS or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Compass Pathways Plc's net margin of --. Compass Pathways Plc's return on equity of -159.15% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About CMPS or BDRX?
Compass Pathways Plc has a consensus price target of $17.00, signalling upside risk potential of 199.3%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 3394.13%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Compass Pathways Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Compass Pathways Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc6 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is CMPS or BDRX More Risky?
Compass Pathways Plc has a beta of 1.933, which suggesting that the stock is 93.331% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock CMPS or BDRX?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or BDRX?
Compass Pathways Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Compass Pathways Plc's net income of -$136.9M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns CMPS or NCNA?
NuCana Plc has a net margin of -- compared to Compass Pathways Plc's net margin of --. Compass Pathways Plc's return on equity of -159.15% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About CMPS or NCNA?
Compass Pathways Plc has a consensus price target of $17.00, signalling upside risk potential of 199.3%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 469425.96%. Given that NuCana Plc has higher upside potential than Compass Pathways Plc, analysts believe NuCana Plc is more attractive than Compass Pathways Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc6 1 0 NCNANuCana Plc0 1 0 -
Is CMPS or NCNA More Risky?
Compass Pathways Plc has a beta of 1.933, which suggesting that the stock is 93.331% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock CMPS or NCNA?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or NCNA?
Compass Pathways Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Compass Pathways Plc's net income of -$136.9M is lower than NuCana Plc's net income of -$378.9K. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns CMPS or TLSA?
Tiziana Life Sciences Ltd. has a net margin of -- compared to Compass Pathways Plc's net margin of --. Compass Pathways Plc's return on equity of -159.15% beat Tiziana Life Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CMPSCompass Pathways Plc-- -$1.44 $72.8M TLSATiziana Life Sciences Ltd.-- -- -- -
What do Analysts Say About CMPS or TLSA?
Compass Pathways Plc has a consensus price target of $17.00, signalling upside risk potential of 199.3%. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 372.68%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Compass Pathways Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Compass Pathways Plc.
Company Buy Ratings Hold Ratings Sell Ratings CMPSCompass Pathways Plc6 1 0 TLSATiziana Life Sciences Ltd.1 0 0 -
Is CMPS or TLSA More Risky?
Compass Pathways Plc has a beta of 1.933, which suggesting that the stock is 93.331% more volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.
-
Which is a Better Dividend Stock CMPS or TLSA?
Compass Pathways Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Pathways Plc pays -- of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPS or TLSA?
Compass Pathways Plc quarterly revenues are --, which are larger than Tiziana Life Sciences Ltd. quarterly revenues of --. Compass Pathways Plc's net income of -$136.9M is higher than Tiziana Life Sciences Ltd.'s net income of --. Notably, Compass Pathways Plc's price-to-earnings ratio is -- while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Pathways Plc is -- versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPSCompass Pathways Plc-- -- -- -$136.9M TLSATiziana Life Sciences Ltd.2,803.69x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
